Generalized Pairwise Comparisons to Assess Treatment Effects
Publié le
JACC Review Topic of the Week We are proud to share the most recent JACC “Review Topic of the Week” featured by the Journal of…
Minimization in randomized clinical trials
Publié le
Tutorial in Biostatistics – Statistics in Medicine IDDI has written a tutorial on Minimization in randomized clinical trials to be…
IDDI at Clinical Trials Strategic Summit EU 2023
Publié le
Meet IDDI’s expert from May 17-18 in London, UK at the 13th Clinical Trials Strategic Summit EU 2023! Schedule a…
ASCO 2023 – Meet IDDI Oncology Experts
Publié le
Schedule a meeting with Dr Marc Buyse, ScD and Dr Everardo Saad, MD at ASCO 2023 We will be happy…
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in HER2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–HER2 Therapy
Publié le
Abstract: Purpose Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts…
Meeting randomization & clinical supply challenges head-on
Publié le
Strategic partnership to pair long-standing clinical research expertise with a best-in-class RTSM system
Adapting the Randomization Algorithm
Publié le
Discover how IDDI biostatistics-driven RTSM helped the Sponsor to avoid serious imbalance between the two randomized arms for the treated…
Adding a stratification factor during the study
Publié le
Discover how a Sponsor reached the overall balance amongst 2 arms by adding a stratification factor.
Optimizing the Drug Supply Strategy
Publié le
Discover how a Sponsor optimized the drug delivery via IDDI’s Proposition of a Predictive Drug Supply Model. PLEASE FILL IN…
Why do so Many Phase III Fail?
Publié le
Randomized controlled trials (RCTs), particularly in phase 3, are the preferred sources of evidence for drug approval and reimbursement decisions….